Celltrion (068270.KS) Stock Price
Celltrion Price
Over the last 19 years Celltrion grew revenue by 27.1% annually, reaching 4.16 T KRW. Earnings per share have grown at 18.3% per year over the last 19 years. For Celltrion, the net margin of 24.7% is down versus 30.3% a few years ago. At today's price the dividend yield works out to roughly 0.40%. The payout ratio is around 10% of earnings. The dividend has grown at 16.9% per year over the past 19 years. The consensus 12-month price target for Celltrion is 255,000.00 KRW, about 43.5% above where the stock trades today. Of 28 analysts, 24 rate the stock a buy — an overall Buy consensus.
Celltrion stock price
Celltrion business model & stock analysis
Frequently asked questions about Celltrion
Celltrion Inc's business model focuses on the development, manufacturing, and sales of biopharmaceutical products. As a global biotechnology company, Celltrion specializes in the production of biosimilars, which are highly similar versions of existing biological medicines. By utilizing advanced technology and innovative research, Celltrion aims to provide affordable and accessible treatments to patients worldwide. The company's key strategies involve extensive research and development efforts to expand its product portfolio, strategic collaborations with international partners, and a commitment to enhancing healthcare accessibility. Through its business model, Celltrion Inc strives to contribute to the advancement of the pharmaceutical industry and positively impact patient lives.
Celltrion Inc is primarily active in the biopharmaceutical industry.
The main competitors of Celltrion Inc in the market include leading biopharmaceutical companies such as Samsung Bioepis, Pfizer Inc., Amgen Inc., and Roche Holding AG. These companies are actively engaged in the development and commercialization of innovative biologic medicines, which may compete with Celltrion's biosimilar products in various therapeutic areas. Celltrion, however, has established a strong market presence and competitive advantage through its expertise in biosimilars manufacturing, research and development capabilities, and strategic partnerships.
Celltrion Inc, a renowned biopharmaceutical company based in South Korea, was founded in 2002. With a strong focus on innovation and research, Celltrion has emerged as a global leader in developing and producing biosimilar and innovative biopharmaceuticals. The company has a diverse portfolio of products, including treatments for autoimmune diseases, cancer, and infectious diseases. Celltrion's commitment towards delivering high-quality therapeutics at an affordable cost has garnered international recognition. By leveraging its expertise in biotechnology, Celltrion continues to strive towards improving healthcare standards and ensuring patient well-being. With a successful track record and a dedication to advancing medical advancements, Celltrion Inc has established itself as a prominent player in the pharmaceutical industry.
Celltrion Inc has achieved several significant milestones. One notable achievement is the approval and successful launch of their biosimilar drugs, such as Inflectra and Remsima, which have had a positive impact on the healthcare industry. Additionally, Celltrion Inc has made advancements in research and development, particularly in the field of monoclonal antibodies for diseases like cancer and autoimmune disorders. The company has also expanded its global reach by securing strategic partnerships and collaborations with other pharmaceutical companies. These milestones demonstrate Celltrion Inc's commitment to innovation and its ability to produce high-quality biopharmaceutical products.
Celltrion Inc is primarily present in South Korea.
Celltrion Inc represents values of innovation, growth, and commitment. The company's corporate philosophy revolves around advancing healthcare through the development of biopharmaceuticals and biosimilars. With a focus on research and development, Celltrion Inc aims to provide effective and affordable treatment options for patients worldwide. By harnessing cutting-edge technology and fostering collaboration, the company strives to make significant contributions to the field of biotechnology. Celltrion Inc's commitment to delivering high-quality products and improving global healthcare standards makes it a prominent player in the pharmaceutical industry.
Analysts currently set an average price target of 249,012.13 KRW for the Celltrion stock (median: 255,000.00 KRW), implying +40.1 % versus the latest price. The consensus is based on 28 analyst ratings.
28 analysts currently rate the Celltrion stock: 25 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Celltrion to generate revenue of 5.58 T KRW and earnings per share of 10,307.63 KRW.
Converted at the current exchange rate, the Celltrion share trades at 115.74 EUR (177,700.00 KRW).
The Celltrion share (068270.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (068270.KS).
Celltrion Inc. is a Korean biotechnology company that specializes in the research, development, and manufacturing of biological drugs. The company was founded in 2002 and is headquartered in Incheon, South Korea. Celltrion Inc. is involved in various business areas, including the development of biosimilars, distribution of biologics, and development of antibiotics.
The expected revenue of Celltrion is 5.58 T KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Celltrion is 1.47 T KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Celltrion is currently 17.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Celltrion stock.
The price-to-sales ratio (P/S) of Celltrion is currently 4.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Celltrion stock.
The Eulerpool Quality Score for Celltrion is 8/10.
The ISIN of Celltrion is KR7068270008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Celltrion is A0RM6K. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Celltrion is 068270.KS. The ticker symbol is used to trade Celltrion shares on the stock exchange.
Celltrion stock
Celltrion Peer Group
Celltrion Ticker
Celltrion FIGI
All fundamentals and in-depth analysis of Celltrion
Our stock analysis for Celltrion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celltrion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.